Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478452 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00478452: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00478452 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478452, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary serous peritoneal cancer given a multivalent DC vaccine, with or without a single dose of cyclophosphamide. Potential benefit may range from no direct benefit to the study participants to stimulation of the subject's own immune system to attack ovarian cancer to prevent relapse.
Interventions
- BIOLOGICAL DC-Ova
- BIOLOGICAL DC Ova with Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478452
The ClinicalTrials.gov registry entry for NCT00478452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DC-Ova is the first listed.
NCT00478452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478452 about?
NCT00478452 is a clinical study titled "Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients". This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary serous peritoneal cancer given a multivalent DC vaccine, with or without a ...
What is the current status of trial NCT00478452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-08. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00478452?
The interventions under investigation include: DC-Ova (BIOLOGICAL), DC Ova with Cyclophosphamide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00478452?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.